Key Takeaways
- Wegovy 7.2 mg is a higher maintenance strength of weekly semaglutide designed as an optional step beyond the standard 2.4 mg ceiling—not a new mandatory target.
- In the 72-week STEP UP trial (over 1,400 adults with obesity), participants on 7.2 mg lost an average of 18.7%–20.7% of body weight versus 15.6% on 2.4 mg.
- Roughly half of participants receiving 7.2 mg achieved 20% or greater total weight loss, bringing semaglutide closer to high-dose tirzepatide outcomes.
- Mild gastrointestinal side effects were somewhat higher (70% vs. 60%), while serious adverse event rates remained low and comparable to 2.4 mg.
Where 7.2 mg Fits Into the Semaglutide Pathway
Standard weekly Wegovy (semaglutide) follows a five-step titration pathway starting at 0.25 mg and progressing through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. For years, 2.4 mg served as the maximum maintenance dose.
The 7.2 mg strength adds an optional higher tier after 2.4 mg rather than replacing existing doses. Crucially, 7.2 mg is not a new universal target—many patients achieve and maintain life-changing health improvements at 1.7 mg or 2.4 mg without ever needing a higher dose.
Key Findings From the Phase 3b STEP UP Trial
Researchers evaluated weekly 7.2 mg semaglutide in STEP UP, a 72-week randomized trial enrolling more than 1,400 adults with obesity (BMI ≥ 30) across 11 countries:
| Outcome Measure (72 Weeks) | Wegovy 2.4 mg | Wegovy 7.2 mg | Clinical Takeaway |
|---|---|---|---|
| Average Body Weight Loss | ~15.6% | ~18.7% (up to 20.7% on-treatment) | Meaningful incremental weight reduction for partial responders |
| Share Losing ≥20% Body Weight | ~30–35% | ~50% | Nearly half crossed the 20% milestone |
| GI Side Effects (Mostly Mild/Mod) | ~60% | ~70% | Expected dose-dependent uptick in nausea/constipation |
| Serious Adverse Events | 11% | 7% (vs. 6% placebo) | Overall serious safety profile remained consistent |
Equally noteworthy: roughly 15% of participants on the standard 2.4 mg dose still lost 25% or more of their starting weight, underscoring that individual biology—not just milligram strength—drives outcomes.
How Does 7.2 mg Semaglutide Compare With Tirzepatide?
In the landmark SURMOUNT-1 study, the highest 15 mg dose of tirzepatide achieved roughly 21% average weight loss. While cross-trial comparisons involve different study populations, STEP UP suggests higher-dose 7.2 mg semaglutide narrows the efficacy gap for patients who respond well to GLP-1-only therapy and prefer staying on semaglutide rather than switching medication classes.
Who Might Be a Candidate for Stepping Up?
You cannot skip early titration stages to start at 7.2 mg. Every patient still progresses gradually from 0.25 mg upward at four-week minimum intervals. A clinician may consider advancing from 2.4 mg to a higher tier only when all four criteria align:
- You have completed at least four weeks on
2.4 mgweekly with consistent adherence. - You are tolerating
2.4 mgcomfortably with minimal or no lingering GI symptoms. - Your weight loss has genuinely plateaued despite consistent nutrition and movement.
- Additional weight reduction is clinically beneficial for your cardiometabolic or joint health goals.
Curious which maintenance strategy fits your body best? Connect with an Amble clinician for individualized metabolic guidance.
Related Clinical Guides
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.